XELEVIA 50 mg (sitagliptin), DPP-4 inhibitor

»  In type 2 diabetics with moderate renal impairment for whom metformin is contraindicated, JANUVIA 50 mg and XELEVIA 50 mg have Marketing Authorisation to improve glycaemic control in monotherapy, in dual therapy in combination with a sulfonylurea or with insulin.

»  For patients with moderate renal impairment (CrCl ≥ 30 to < 50 ml/min), the dosage is 50 mg sitagliptin once daily.

»  In dual therapy with insulin or a sulfonylurea, in the absence of any clinical data, the efficacy/adverse effect ratio of JANUVIA 50 mg and XELEVIA 50 mg is poorly established in type 2 diabetics with moderate renal impairment. Sitagliptin 50 mg can possibly be combined with a sulfonylurea, but is not recommended with insulin.